Videos

Dr. Fouad Kettani’s Experience Using DeepDx Prostate: A Testimonial

We are thrilled to share the insights of Dr. Fouad Kettani, who recently tested our DeepDx Prostate solution. Dr. Kettani highlighted several positive aspects of our product, particularly emphasizing its ease of use and the depth of AI-generated results. He...

June 4, 2024

News

Deep Bio Unveils Research Findings on Performance Evaluation of AI Algorithm for Breast Cancer An...

Deep Bio utilizes deep learning-based algorithms to differentiate breast cancer lesions accurately, optimizing diagnostic accuracy SEOUL, SOUTH KOREA, May 21, 2024 Deep Bio today announced the publication of a study evaluating the performance of its AI algorithm for breast cancer...

May 21, 2024

Publications

[Posters] AACR 2024 – Morphological Feature Discrepancies in Wild-type vs. BRCA1/BRCA2 Muta...

JaeHeon Lee1), Hyunil Kim1), Yongeun Lee1), Yoon-La Choi2), Kyungsoo Jung2), Tae-Yeong Kwak1), Sun Woo Kim1), Hyeyoon Chang1) 1) Deep Bio Inc. | 2) Samsung Medical Center

April 12, 2024

Publications

[Posters] AACR 2024 – Enhancing Multi-organ Frozen Section Cancer Discrimination Model by S...

Joonho Lee1), Joonyoung Cho1), Junho Lee1), Yoon-La Choi2), Kyungsoo Jung2), Tae-Yeong Kwak1), Sun Woo Kim1), Hyeyoon Chang1) 1) Deep Bio Inc. | 2) Samsung Medical Center | 3) Sungkyunkwan University School of Medicine

April 12, 2024

Publications

[Posters] AACR 2024 – Semi-Automated Ki-67 Index Assessment Using Top-k Hotspot Recommendat...

Hyeon Seok Yang1), Yunseob Hwang1), Yongeun Lee1), Kyungsoo Jung2), Minjung Sung2), Tae-Yeong Kwak1), Sun Woo Kim1), Hyeyoon Chang1) 1) Deep Bio Inc. | 2) Samsung Medical Center

April 12, 2024

News

[BioSpectrum Asia] AI will be integrally involved in not only the diagnosis of cancer but also in...

South Korea based Deep Bio, a pioneering artificial intelligence (AI) healthcare firm focused on cancer pathology, is making waves in the industry. Their recent involvement in the innovative CancerX initiative, part of the White House Cancer Moonshot programme, marks a...

April 1, 2024

News

Deep Bio to Present Research Findings at Poster Sessions during AACR Annual Meeting 2024

Three posters will be presented at the AACR Annual Meeting 2024 to spotlight Deep Bio's pioneering research and advancements in AI within digital pathology.     SEOUL, SOUTH KOREA, March 28, 2024 Deep Bio, a frontrunner in AI-powered cancer diagnostics,...

March 28, 2024

Publications

[Posters] USCAP 2024 – Enhancing Multi-organ Frozen Section Cancer Discrimination Model wit...

Joonho Lee1), Junho Lee1), Yoon-La Choi2), Kyungsoo Jung2), Tae-Yeong Kwak1), Sun Woo Kim1), Hyeyoon Chang1) 1) Deep Bio Inc. | 2) Samsung Medical Center | 3) Sungkyunkwan University School of Medicine

March 25, 2024

Publications

[Posters] USCAP 2024 – Enhancing Frozen Section Whole Slide Image Classification by Style T...

Junho Lee1), Joonho Lee1), Soyeon Jang1), Yoon-La Choi2), Kyungsoo Jung2),3), Tae-Yeong Kwak1), Sun Woo Kim1), Hyeyoon Chang1) 1) Deep Bio Inc. | 2) Samsung Medical Center | 3) Sungkyunkwan University School of Medicine

March 25, 2024

Publications

[Posters] USCAP 2024 – Storage Optimization for Digital Pathology Images: Super-Resolution ...

Soyeon Jang1), Joonho Lee1), Junho Lee1), Tae-Yeong Kwak1), Sun Woo Kim1), Hyeyoon Chang1) 1) Deep Bio Inc.

March 25, 2024

Publications

[Posters] USCAP 2024 – A Deep Learning-Based Tumor Area Identification Using a Semi-Supervi...

Yunseob Hwang1), Hyeon Seok Yang1), Yoon-La Choi2), Kyungsoo Jung2), Young Kee Shin3), 4), Ji-Hye Nam3), 4), Jun Young Choi5), Kyung-Eui Park5), Tae-Yeong Kwak1), Sun Woo Kim1), Hyeyoon Chang1) 1) Deep Bio Inc. | 2) Samsung Medical Center | 3) Seoul...

March 25, 2024

News

Deep Bio to Present Their Research Findings at The Poster Sessions During the USCAP 113th Annual ...

SEOUL, SOUTH KOREA, March 19, 2024 /EINPresswire.com/ -- Four research results will be presented to validate Deep Bio’s pioneering research and breakthroughs in AI advancements in digital pathology. Link to the Article  Deep Bio, a leader in AI-driven solutions for...

March 19, 2024

Events

Deep Bio to Participate in USCAP 2024

March 1, 2024

News

Deep Bio’s DeepDx Prostate Featured in CancerX’s Solutions Catalog, Pioneering Digita...

SEOUL, SOUTH KOREA, February 5, 2024 /EINPresswire.com/ -- Deep Bio, a pioneer of AI-powered cancer diagnostics solutions, proudly announced the inclusion of DeepDx Prostate in CancerX's Solutions Catalog. This significant participation positions Deep Bio as a key contributor to CancerX's...

February 5, 2024

News

Deep Bio Announces Launch of DeepDx Prostate in Switzerland, Paving the Way for European Expansion

SEOUL, SOUTH KOREA, JANUARY 31, 2024 / PRNewswire/ - Deep Bio's AI-powered Prostate Cancer Diagnostic Software is Now Available on the Swiss Market, Advancing Healthcare Access Across Europe. Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, proudly announced...

January 31, 2024

News

Deep Bio becomes first Korean cancer diagnostic AI company to win CES Innovation Award

SEOUL, SOUTH KOREA, NOVEMBER 21, 2023 / PRNewswire/ - Won the CES Innovation Award for pioneering a new milestone in Korean cancer diagnosis AI solutions. Link to the Article  Deep Bio announced today that it has been awarded the CES...

November 21, 2023

News

Deep Bio Joins CancerX to Revolutionize Cancer Diagnosis and Prognosis with AI Expertise

SEOUL, SOUTH KOREA, NOVEMBER 7, 2023 / PRNewswire/ - Deep Bio, a leading AI healthcare company specializing in deep learning and cancer pathology, is proud to announce its participation in the groundbreaking CancerX initiative, a public-private partnership unveiled earlier this...

November 7, 2023

News

Deep Bio Earns Coveted Spot in Korea AI Startup 100 List for the Third Consecutive Year

Link to the Article  SEOUL, South Korea, Oct. 4, 2023 /PRNewswire/ -- Deep Bio, a leader in artificial intelligence (AI)-powered cancer diagnostics, announced today that it has been named to the Korea AI Startup 100 list. This prestigious list, representing...

October 4, 2023

News

Deep Bio Welcomes Grant Carlson as Chief Commercial Officer

Seasoned Industry Expert Joins Deep Bio to Drive Commercial Growth and Expansion. Deep Bio appoints Grant Carlson as the company’s Chief Commercial Officer. SEOUL, SOUTH KOREA (PRWEB) JULY 30, 2023 - Deep Bio, a leader in artificial intelligence (AI)-powered cancer...

July 30, 2023

News

Deep Bio Secures Spot in South Korean Government’s Prestigious “Super Gap Startup 100...

An award ceremony was held on July 4th, where Director Byeonggweon Lee from the Korean Ministry of SMEs and Startups (MSS) presented a plaque and expressed confidence in Deep Bio’s potential. SEOUL, SOUTH KOREA (PRWEB) JULY 07, 2023 - Deep Bio Inc., a...

July 7, 2023

News

Deep Bio’s AI Algorithm Helps Risk Stratification for Prostate Cancer

Collaborative research by Deep Bio and Dr. Lotan research team at Johns Hopkins Medicine was revealed at AUA 2023 SEOUL, SOUTH KOREA (PRWEB) MAY 11, 2023 - Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics...

May 11, 2023

Publications

[Abstract] ASCO 2023 – Validation of AI-based postoperative nomograms for biochemical recur...

Authors: JaeHeon Lee, Tae-Yeong Kwak, Joonyoung Cho, Sun Woo Kim, Hyeyoon Chang, Hong Koo Ha Organizations Deep Bio Inc., Seoul, South Korea, Pusan National University, Pusan, South Korea Background After radical prostatectomy (RP), a steep increase in PSA level is...

May 9, 2023

Publications

[Abstract] ASCO 2023 – Deep learning-based histomorphological pattern profiles for effectiv...

Authors: JaeHeon Lee, Tae-Yeong Kwak, Joonyoung Cho, Sun Woo Kim, Hyeyoon Chang Organizations Deep Bio Inc., Seoul, South Korea Background Prostate cancer affects millions of men globally and biochemical recurrence (BCR) is an important indicator of its progression. With the...

May 6, 2023

Publications

[Abstract] ASCO 2023 – Exploring the efficacy of a continuous form of the histologic grade ...

Authors: Tae-Yeong Kwak, JaeHeon Lee, Joonyoung Cho, Sun Woo Kim, Hyeyoon Chang Organizations Deep Bio Inc., Seoul, South Korea Background Adenocarcinoma of the prostate is the second most common type of cancer among men worldwide. The Gleason grading system remains...

May 2, 2023

Publications

[Abstract] ASCO 2023 – Algorithm-based histologic grade and tumor ratio for radical prostat...

Authors: Tae-Yeong Kwak, JaeHeon Lee, Joonyoung Cho, Sun Woo Kim, Hyeyoon Chang, Hong Koo Ha Organizations Deep Bio Inc., Seoul, South Korea, Pusan National University, Pusan, South Korea Background The histologic grade (Gleason score) as well as the tumor ratio...

May 1, 2023

Publications

[Posters] AACR 2023 – Protein Receptor Prediction Model Using Only H&E Stained Images ...

April 2, 2023

Publications

[Posters] AACR 2023 – Clonal Evaluation of ERG/SPINK1 Status to Determine Disease Progressi...

April 1, 2023

News

Deep Bio’s Novel Study Results Reaffirm Its Global Presence

USCAP 2023 is Deep Bio’s sixth consecutive year of presenting research abstracts SEOUL, SOUTH KOREA (PRWEB) MARCH 14, 2023 - Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software shared three research abstracts at the United States...

March 14, 2023

Publications

[Posters] USCAP 2023 – Evaluation of Attention-based Tumor Area Segmentation Deep Learning ...

March 1, 2023

Publications

[Posters] USCAP 2023 – Comparative Analysis of c-MET Expression Using Image Analysis Model ...

March 1, 2023

News

Deep Bio and Visiopharm Announce a Collaborative Integration of a Clinical-Grade AI Prostate Canc...

Pathologists can now have access to the state-of-the-art AI prostate cancer grading solution                                  SEOUL, SOUTH KOREA (PRWEB) NOVEMBER 15, 2022 - Deep Bio, a leading AI biotech...

November 15, 2022

News

Deep Bio Inc. successfully integrates DeepDx® Prostate algorithm into the HALO AP® platform from ...

Discover how Deep Bio Inc. (딥바이오) successfully integrates their DeepDx® Prostate algorithm into the HALO AP® platform from Indica Labs. Read the exciting new case study!

October 31, 2022

News

Deep Bio Acquires ISO 27001 Certification for an Information Security Management System

Enhanced security and reliability through adherence to globally recognized information security standards                SEOUL, SOUTH KOREA (PRWEB) OCTOBER 27, 2022 - Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software,...

October 27, 2022

News

Deep Bio Selected as ‘Korea AI Startup 100’ for Two Consecutive Years

AI experts expect Deep Bio to succeed in the healthcare industry with its innovative technology SEOUL, SOUTH KOREA (PRWEB) OCTOBER 21, 2022 - Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics support software, announced that it has...

October 21, 2022

News

Deep Bio Welcomes New Advisors to Accelerate Its Growth in Global Market

The new advisors will focus on Deep Bio’s overseas business expansion as well as strengthening its expertise in cancer pathology.                                    SEOUL, SOUTH KOREA...

October 11, 2022

News

Deep Bio’s AI Support for Prostate Cancer Diagnosis will be Deployed at Five Korean Hospitals

DeepDx®-Prostate Pro, designated as an Innovative Product by the Korea Public Procurement Service, is expected to improve pathology workflows in real clinical settings SEOUL, SOUTH KOREA (PRWEB) OCTOBER 10, 2022 - Deep Bio, a pioneer in medical AI for digital pathology and cancer...

October 10, 2022

Publications

[ARTICLE] Modern Pathology – Artificial intelligence system shows performance at the level ...

MODERN PATHOLOGY ARTICLE | VOLUME 35, ISSUE 10, P1449-1457, OCTOBER 2022 Authors: Minsun Jung, Min-Sun Jin, Chungyeul Kim, Cheol Lee, Ilias P. Nikas, Jeong Hwan Park, Han Suk Ryu Abstract Accurate diagnosis and grading of needle biopsies are crucial for prostate...

October 1, 2022

News

Deep Bio Acquires MDSAP Certification, Paving the Way for Global Expansion

Demonstrated globally-recognized standards in safety and quality management as a medical software manufacturer. SEOUL, SOUTH KOREA (PRWEB) AUGUST 16, 2022 - Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, announced that it has been recently granted Medical Device Single Audit...

August 16, 2022

News

Deep Bio’s AI Support for Cancer Diagnosis has been Designated as an Innovative Product by the Ko...

This designation marks the Korean government’s recognition of innovation for DeepDx®-Prostate Pro. SEOUL, SOUTH KOREA (PRWEB) JULY 25, 2022 - Deep Bio, a pioneer in medical AI for digital pathology and cancer diagnostics software, announced that its AI solution for grading the...

July 25, 2022

News

Deep Bio’s AI-based Cancer Diagnostic Software Demonstrated Uropathologist-level Performance

Independent external validation study results of Deep Bio’s AI algorithm for prostate cancer diagnosis were published in the Modern Pathology   SEOUL, SOUTH KOREA (PRWEB) MAY 13, 2022 - Deep Bio, a pioneer in medical AI for digital pathology and...

May 13, 2022

Publications

[Posters] AACR 2022 – Breast Cancer Survival Analysis with the Size of the Infiltrative Can...

April 16, 2022

Publications

[Posters] AACR 2022 – Automated Gleason Grading of Digitized Frozen Section Prostate Tissue...

April 15, 2022

Publications

[Posters] AACR 2022 – A Deep Learning based Pancreatic Adenocarcinoma Survival Prediction M...

April 13, 2022

Publications

[Posters] AACR 2022 – Recurrence Risk Prediction Based on Automatic Histologic Analysis of ...

April 12, 2022

Publications

[Posters] AACR 2022 – Molecular Mapping of Prostate Cancer on Whole Mount Prostatectomy Spe...

April 12, 2022

News

Deep Bio Presents Research Results of AI-based Cancer Diagnosis and Prognosis at the AACR Annual ...

Five abstracts in prostate and breast cancers, Deep Bio’s main research areas, are presented during the online sessions. SEOUL, SOUTH KOREA (PRWEB) APRIL 11, 2022 - Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, presented five abstracts in regards...

April 11, 2022

News

Join Deep Bio at AACR 2022!

Join Deep Bio at AACR 2022! At this year’s AACR, Deep Bio will present both on-site and virtually! Visit us at booth #1461 to share your thoughts on the role of digital pathology and AI in cancer research. Also, don’t...

April 1, 2022

Videos

[Interview] Deep Bio CEO Interview – SBS Biz

March 30, 2022

News

Deep Bio Presented Deep Learning-based Cancer Research at the USCAP 111th Annual Meeting

Five researches in regards to deep learning-based cancer diagnosis and prognosis highlighted SEOUL, SOUTH KOREA (PRWEB) MARCH 23, 2022 - Deep Bio, a pioneer in medical AI for pathologic cancer diagnostics, announced five research studies at the 2022 United States...

March 23, 2022

Publications

[Posters] USCAP 2022 – Considering Uncertainty Improves Deep Learning-based Lung Cancer Sub...

March 19, 2022

Publications

[Posters] USCAP 2022 – Ki-67 Index Regression Using Fully Convolutional Regression Network ...

March 18, 2022

Publications

[Posters] USCAP 2022 – Breast Cancer Survival Analysis through the Extracted Feature from t...

March 18, 2022

Publications

[Posters] USCAP 2022 – Automatic Histological Grading of Breast Cancer Resection Tissue

March 17, 2022

Publications

[Posters] USCAP 2022 – Deep Learning-based Automated Detection of Prostate Cancer Lesions

March 17, 2022

News

Join Deep Bio at USCAP 2022

    Join Deep Bio at USCAP 2022 We are excited to finally meet you in person at USCAP 2022! Explore how Deep Bio’s AI solutions have shaped digital pathology. Learn about the new insights from our studies. Deep Bio...

March 15, 2022

News

Deep Dive into High-Level Diagnostics

AI-mediated analysis of prostate biopsies enables faster and better diagnoses Healthcare systems are struggling with a pathologist shortfall. In the US, the number of active pathologists dropped by 18 percent from 2007 to 2017; in South Korea, 65 pathology residency...

October 21, 2021

News

[Interview] [Innovative Startups] Deep Bio to revolutionize prostate cancer diagnosis with AI pla...

Korea has emerged as a "technology powerhouse" as the nation is seeing new innovative startups that are working on visualizing the once futuristic technology to real life. Korea Biomedical Review met with innovative CEOs from various healthcare startups to hear...

September 4, 2021

News

Deep Bio Announces Research Collaboration with a Major Cancer Institute

Deep Bio renews Research Collaboration Agreement with Dana-Farber Cancer Institute SEOUL, South Korea, July 22, 2021 - Deep Bio, a leading company in digital pathology and cancer diagnostics, today announced a renewal of their Research Collaboration Agreement with Dana-Farber Cancer...

July 22, 2021

News

Deep Bio Collaborates with ARUP in AI Clinical Implementation Research

ARUP applies Deep Bio’s deep learning-based prostate cancer detection and classification solution for research SEOUL, SOUTH KOREA (PRWEB) JULY 16, 2021– Deep Bio, a leading company in AI cancer diagnostics, announced a Research Collaboration Agreement with ARUP Laboratories, a top...

July 16, 2021

News

Deep Bio Renews Software License Agreement with Stanford Medicine

Deep Bio provides its AI-based prostate cancer detection software for research SEOUL, SOUTH KOREA (PRWEB) JULY 16, 2021 - Deep Bio, a leading company in digital pathology and cancer diagnostics, announced an extension of Software License Agreement with Stanford University...

July 16, 2021

News

Gestalt Diagnostics and Deep Bio Announce Strategic Relationship to Deliver Image Analysis Algori...

Spokane, WA, and Seoul, Korea (July 14, 2021) – Gestalt Diagnostics and Deep Bio today announced their strategic relationship on the development of an integrated workflow for pathologists to use Artificial Intelligence algorithms directly within Gestalt’s PathFlow® platform. Deep Bio’s algorithm analyzes...

July 14, 2021

News

Deep Bio Presents its Novel Deep Learning-based Gleason Grading System in npj Digital Medicine

Deep Bio developed a novel deep learning-based prostate cancer detection model that demonstrates superb performance trained by a weakly supervised learning method  Seoul, South Korea, July 1, 2021 - Deep Bio today announced that it published research results on a...

July 1, 2021

News

Embracing Pathology’s Digital Revolution with Deep Bio

Deep Bio stands at the front and center of digital transformation with DeepDx® Prostate Digital pathology is on the rise – and, with it, artificial intelligence’s role in the pathology workflow. Many pathologists are embracing the change – often young...

March 22, 2021

News

Deep Bio, Clinical Trial for ‘AI-powered Prostate Cancer Diagnosis’ in Korea

Seoul, South Korea- Deep Bio announced today that it had officially commenced clinical trial on ‘DeepDx-Prostate,’ a prostate biopsy AI-based diagnostic software. Deep Bio has recently received clinical trial plan approval from the Ministry of Food and Drug Safety for...

April 11, 2019

News

Deep Bio Inc. ranks 1st in the CAMELYON17 Grand Challenge from post submitting i…

The Deep Bio research team set the record in the Camelyon Challenge 17’ currently positioning them in first place. The Camelyon17 Grand Challenge is a global competition organized by the Diagnostic Image Analysis Group (DIAG) and the Radboud University Medical...

February 12, 2019

News

Deep Bio launches AI-diagnostic software on prostate cancer ..”grants certifications”

Deep Bio announced today that it had released its artificial intelligence (AI) diagnostic products for the first time in the domestic press. The company’s first AI software product ‘Deep Dx’ detects prostate cancer using H&E stained prostate biopsy WSI images....

December 13, 2018

News

Deep Bio recieves ISO 13485

Deep Bio, an AI-powered medical service startup company, today announced that it had granted ISO 13485:2016 certification for its Quality Management System (QMS). ISO 13485 is an internationally recognized standard for companies involved in the medical industry to obtain compliance...

September 17, 2018

News

AI-driven diagnositc company, Deep Bio Inc. closes $5 Million USD in Series A

On May 28th, AI startup ‘Deep Bio’ succeeded in Series A funding from various venture capital companies in Korea. Deep Bio is a medicalAI company that develops cancer diagnostic software products. While the products are still under development, it is...

March 2, 2018

News

Deep Bio Inc., takes on a challenge to develop software using AI

“Learning amount ↑ · Error ↓” Utilization as a clinical supporting device .. Artificial Intelligence (AI) has now made its headway into the biotech industry. Google is presenting a new technology revolution where systems such as ‘Alpha Go’ are involved...

September 18, 2017

News

DeepBio, ‘prostate cancer’ detection using AI ..closes seed rounding

Deep Bio, is a start-up company that develops artificial intelligence (AI) to diagnose prostate cancer. There are diagnostic imagining methods such as X-rays and computed tomography (CT) to detect prostate cancer, but Deep Bio uses H&E stained biopsy digital whole...

August 13, 2017